Table 1 Characteristics of included studies
Study | Design | Location | Duration | Patient population | Sample size (male sex %) | Patients with VRE BSI | VRE BSI sex ratio (m:f) |
|---|---|---|---|---|---|---|---|
Chen et al. [23] | Retrospective cross-sectional study | Changhua, Taiwan | 2010–2014 | All admitted patients with enterococcal BSI | 279 (NM) | 36 | 4:5 |
Ford et al. [24] | Cohort study | Salt Lake City, USA | 2006–2014 | Admitted HSCT patients with enterococcal BSI | 161 (72%) | 10 | 1:1 |
Xie et al. [25] | Retrospective chart review | Melbourne, Australia | 2008–2013 | All admitted patients with VRE BSI | 96 (52%) | 96 | 10:9 |
Ye et al. [26] | Retrospective cohort study | Taoyuan, Taiwan | 2011–2015 | Admitted patients > 18 years with VRE BSI | 210 (53%) | 210 | 10:9 |
Johnstone et al. [27] | Matched case-control study | Ontario, Canada | 2009–2013 | All admitted patients with VRE BSI matched to 3 controls | 868 (60%) | 217 | 3:2 |
Ryan et al. [28] | Retrospective cohort study | Dublin, Ireland | 2009–2012 | All admitted patients with VRE BSI | 75 (60%) | 75 | 3:2 |
Gouliouris et al. [29] | Nested case-control study | Cambridge, UK | 2006–2012 | Admitted patients with VRE BSI matched 1:1 to controls | 455 (60%) | 235 | 8:5 |
Kramer et al. [30] | Retrospective cohort study | Berlin, Germany | 2008–2015 | All admitted patients with enterococcal BSI | 1160 (61%) | 103 | 2:1 |
Bae et al. [31] | Retrospective cohort study | Seoul, Korea | 2010–2017 | Admitted patients ≤ 18 years with underlying malignancies and enterococcal BSI | 30 (70%) | 11 | 9:2 |